CXCR
Os CXCRs são uma subclasse de GPCRs que se ligam a quimiocinas, pequenas proteínas sinalizadoras que guiam o movimento de células imunológicas em direção a locais de inflamação, infecção ou lesão. Os CXCRs desempenham papéis cruciais nas respostas imunológicas, metástase do câncer e doenças inflamatórias. Moduladores de CXCRs estão sendo investigados por seu potencial no tratamento de doenças autoimunes, câncer e condições inflamatórias crônicas. Na CymitQuimica, oferecemos uma gama de moduladores de CXCRs de alta qualidade para apoiar sua pesquisa em imunologia, oncologia e inflamação.
Foram encontrados 147 produtos de "CXCR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Quetmolimab
CAS:<p>Quetmolimab is a humanized monoclonal antibody targeting chemokine ligand 1 (CX3CL1) that can be used to study rheumatoid arthritis.</p>Pureza:SDS-PAGE:95% SEC-HPLC:97.59%Cor e Forma:LiquidPeso molecular:150 kDaDelmetacin
CAS:<p>Delmetacin: a non-steroidal anti-inflammatory drug with analgesic properties, inhibits CXCR1.</p>Fórmula:C18H15NO3Pureza:98.14%Cor e Forma:SolidPeso molecular:293.32VUF11207 fumarate
CAS:<p>VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).</p>Fórmula:C31H39FN2O8Pureza:97.98%Cor e Forma:SolidPeso molecular:586.65Motixafortide TFA(664334-36-5,Free)
<p>Motixafortide TFA is a CXCR4 antagonist with ~1 nM IC50, promoting AML apoptosis by modulating miR-15a/16-1 and downregulating ERK and BCL-2.</p>Fórmula:C99H145F4N33O21S2Pureza:>99.99%Cor e Forma:SolidPeso molecular:2273.54LY2510924 acetate(1088715-84-7 free base)
<p>Ly2510924 acetate is an potent and selective CXCR4 antagonist. It prevents the binding of SDF-1 to CXCR4 with an IC50 of 0.079 nM.</p>Fórmula:C64H91N13O13Pureza:97.32%Cor e Forma:SolidPeso molecular:1250.49AMG 487
CAS:<p>AMG 487: potent CXCR3 antagonist, blocks CXCL10/CXCL11 binding, IC50s: 8.0/8.2 nM.</p>Fórmula:C32H28F3N5O4Pureza:99.82% - 99.89%Cor e Forma:SolidPeso molecular:603.59Eldelumab
CAS:<p>Eldelumab (BMS-936557) is an anti-IP-10 IgG 1 monoclonal antibody.Eldelumab has anti-inflammatory activity and is used to study rheumatoid arthritis.</p>Pureza:95%Cor e Forma:LiquidReparixin L-lysine salt
CAS:<p>Reparixin L-lysine salt (Repertaxin L-lysine salt) is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.</p>Fórmula:C20H35N3O5SPureza:99%Cor e Forma:SolidPeso molecular:429.57PF-06835375
CAS:<p>PF-06835375 is a humanized IgG1 antibody that selectively targets CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like cells (cTfh). It is applicable for research into systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).</p>Cor e Forma:LiquidITIC-4F
CAS:<p>ITIC-4F: a postfullerene IDTT electron acceptor for high-efficiency PSCs, relevant in binary, ternary, and tandem setups.</p>Fórmula:C94H78F4N4O2S4Pureza:98%Cor e Forma:SolidPeso molecular:1499.92ITIC
CAS:<p>"ITIC, a non-fullerene acceptor with high Tg of 180°C, shows excellent thermal stability and a low glass-crystal transition, plus unique crystallization."</p>Fórmula:C94H82N4O2S4Pureza:98%Cor e Forma:SolidPeso molecular:1427.96TC14012
CAS:<p>CXCR4 antagonist and ACKR3 (CXCR7) agonist (EC50 = 350 nM for CXCR7).</p>Fórmula:C90H140N34O19S2Pureza:98%Cor e Forma:SolidPeso molecular:2066.43CTCE-9908
CAS:<p>CXCR4 blocker; triggers cell division failure in ovarian cancer, boosts taxol and docetaxel treatment effects, proven in mice.</p>Fórmula:C86H147N27O23Pureza:98%Cor e Forma:SolidPeso molecular:1927.27PDE4D inhibitor 1
<p>PDE4-IN-1 is a PDE4 inhibitor characterized by high potency (IC50: 8.6 nM) and superior selectivity over other PDE subtypes. This compound inhibits the release of inflammatory cytokines and chemokines. Additionally, PDE4-IN-1 significantly restores the damaged cAMP-CREB signaling pathway, inhibits proliferation, and promotes differentiation to reverse psoriasis formation.</p>Cor e Forma:Odour SolidCXCR4 antagonist 2
CAS:<p>CXCR4 antagonist 2 is a CXCR4 antagonist with an IC 50 value of 47 nM.</p>Fórmula:C25H36N6Cor e Forma:SolidPeso molecular:420.605CXCR7 modulator 1
CAS:<p>CXCR7 modulator 1 is an effective and orally bioavailable peptoid hybrid CXCR7 modulator with Ki of 9 nM.</p>Fórmula:C48H57F2N7O7SPureza:98%Cor e Forma:SolidPeso molecular:914.07VB-85247
<p>VB-85247 is a STING agonist that, by activating the STING pathway, induces the upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as the maturation and activation of dendritic cells. It can lead to the regression of tumors within the bladder and is applicable in bladder cancer research.</p>Cor e Forma:Odour SolidBam 12P
CAS:<p>Bam 12P is a Pro-Met-enkephalin precursor that is isolated from the bovine adrenal medulla.</p>Fórmula:C62H97N21O16SPureza:98%Cor e Forma:SolidPeso molecular:1424.64KRH-3955 hydrochloride
CAS:<p>KRH-3955 hydrochloride is an orally available CXCR4 blocker with IC50 of 0.61 nM and EC50 of 0.3-1.0 nM against X4 HIV-1.</p>Fórmula:C28H48Cl3N7Cor e Forma:SolidPeso molecular:589.09CXCR4 antagonist 1
CAS:<p>CXCR4 antagonist 1 is a potent inhibitor of the CXCR4 receptor, with notable anti-HIV activity.</p>Fórmula:C27H43N7Cor e Forma:SolidPeso molecular:465.69AZD4721
CAS:<p>AZD4721, an oral CXCR2 antagonist, may be researched for treating inflammation.</p>Fórmula:C19H25FN4O5S2Cor e Forma:SolidPeso molecular:472.55Polyphemusin II-Derived Peptide
CAS:<p>T140, a Polyphemusin II-derived peptide, inhibits HIV-1 entry and blocks anti-CXCR4 antibody (12G5) binding.</p>Fórmula:C90H141N33O18S2Cor e Forma:SolidPeso molecular:2037.42Peptide R
CAS:<p>Peptide R, a cyclic CXCR4 antagonist, remodels tumor stroma, aiding cancer research.</p>Fórmula:C39H59N13O8S2Cor e Forma:SolidPeso molecular:902.1CXCL-CXCR1/2-IN-1
CAS:<p>CXCL-CXCR1/2-IN-1 is an ELR+CXCL-CXCR1/2 pathway inhibitor with anticancer activity and can be used in the study of cardiovascular disease.</p>Fórmula:C14H8Cl2N4O3SPureza:99.4%Cor e Forma:SoildPeso molecular:383.21CXCR2 Probe 1
<p>CXCR2Probe 1 (Compound[18F]16b) is a selective ligand for CXCR2 and serves as a radioactive tracer for PET imaging of neutrophils in inflammatory diseases.</p>Fórmula:C20H24FN3O4Peso molecular:389.17508CCR7 antagonist 1
<p>CCR7 antagonist1 (30c) functions as a dual antagonist, targeting CXCR2 with an IC50 of 11.02 μM and CCR7 with an IC50 of 0.43 μM.</p>Fórmula:C13H22N6OSPeso molecular:310.15758CXCR4-IN-3
<p>CXCR4-IN-3 (compound XVI) is an orally active inhibitor targeting the inflammation-related receptor CXCR4, with an IC50 of 3.2 nM. It exhibits potent anti-chemotactic effects, with an inhibition rate of 79.19±2.33%. Additionally, CXCR4-IN-3 possesses anti-inflammatory properties and can be utilized in research on IBD (inflammatory bowel disease).</p>CXCL8 (54-72)
<p>CXCL8 (54-72) is a C-terminal peptide segment of the chemokine CXCL8. This peptide features a long, highly positively charged C-terminal region that interacts with the negative charges on glycosaminoglycans (GAG) to facilitate binding. CXCL8 (54-72) inhibits neutrophil adhesion and migration, as well as adhesion to endothelial cells. It is useful in studying the role of chemokines in inflammatory responses.</p>Fórmula:C107H173N33O30Peso molecular:2400.30261RCP168
<p>RCP168 is a highly selective and potent CXCR4 receptor antagonist with an IC50 of 5 nM. It exhibits superior capacity to inhibit HIV-1 (Human Immunodeficiency Virus type 1) from entering host cells via the CXCR4 receptor compared to natural chemokines. RCP168 suppresses HIV-1 infection by blocking viral binding sites or inducing receptor internalization. It can be utilized in research to study interactions between the CXCR4 receptor and other chemokine receptors.</p>Fórmula:C365H585N105O95S5Peso molecular:8119.27766BVT173187
CAS:<p>BVT173187 is a neutrophil formyl peptide receptors (FPR1) inhibitor.</p>Fórmula:C14H10Cl3NO2Cor e Forma:SolidPeso molecular:330.59CX4338
CAS:<p>CX4338 is a CXCL8-mediated chemotaxis inhibitor.</p>Fórmula:C22H24N2OSCor e Forma:SolidPeso molecular:364.50NI-0801
<p>NI-0801 (Anti-CXCL10 / IP-1) is a CHO-expressed humanized monoclonal antibody targeting CXCL10/IP-10 for the study of vitiligo and biliary cirrhosis.</p>Pureza:97.9% (SDS-PAGE); 99.4% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.4% (SEC-HPLC)Cor e Forma:Odour LiquidCyclic MKEY
CAS:<p>MKEY peptide inhibits CXCL4-CCL5, reduces atherosclerosis and aneurysm, neuroinflammatory effects unknown.</p>Fórmula:C113H174N28O34S2Pureza:98%Cor e Forma:SolidPeso molecular:2532.89TC14012 TFA
<p>TC14012 TFA is a peptide-mimetic CXCR4 antagonist and CXCR7 agonist that promotes the recruitment of β-arrestin by CXCR7 .</p>Fórmula:C92H141F3N34O21S2Pureza:96.31%Cor e Forma:SolidPeso molecular:2180.44Balixafortide TFA (1051366-32-5 free base)
<p>Balixafortide TFA is a selective CXCR4 antagonist with IC50 < 10nM, over 1000x preference for CXCR4, and blocks β-arrestin and calcium flux.</p>Fórmula:C82H113N22F3O23S2Pureza:98%Cor e Forma:SolidPeso molecular:1896.05vMIP-II (1-21) TFA
<p>vMIP-II (1-21) (NT21MP) TFA (TFA is a potent inhibitor of CXCR4. This compound interacts broadly with CC and CXC chemokine receptors. Furthermore, vMIP-II (1-21) TFA inhibits CXCR4 by competing for binding sites with 125I-SDF-1R, exhibiting an IC50 value of 190 nM.</p>Cor e Forma:Odour SolidSDF-1α (human)
CAS:<p>SDF-1α (human) serves as a chemotactic agent for mononuclear cells through its interaction with the CXCR4 receptor, facilitating critical biological processes</p>Fórmula:C356H578N106O93S4Pureza:98%Cor e Forma:SolidPeso molecular:7959.34E70K
<p>E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate</p>Fórmula:C108H178N34O28Pureza:98%Cor e Forma:SolidPeso molecular:2400.784-Amino-D-phenylalanine
CAS:<p>4-Amino-D-phenylalanine ([D-Phe(4-NH2)]) is a cyclic pentapeptide that inhibits the binding of CXCL12 to CXCR4 in FC131, with an IC50 value of 0.1 μM.</p>Fórmula:C9H12N2O2Cor e Forma:SolidPeso molecular:180.2DOTA-CXCR4-L
<p>DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer</p>Fórmula:C58H78N16O14Pureza:98%Cor e Forma:SolidPeso molecular:1223.34Chemokine Inhibitor Library
<p>A unique collection of xnum chemokines or chemokine receptors targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidVUF-11222
CAS:<p>VUF-11222 is an agonist of high affinity non-peptide CXCR3 agonist (pKi = 7.2).</p>Fórmula:C25H31BrINPureza:99.82%Cor e Forma:SolidPeso molecular:552.33LY2510924
CAS:<p>LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM).</p>Fórmula:C62H88N14O10Cor e Forma:SolidPeso molecular:1189.45ACT-1004-1239
CAS:<p>ACT-1004-1239 is a CXCR7 antagonist with immunomodulatory and myelination-promoting effects, used for research on inflammatory demyelinating diseases.</p>Fórmula:C27H28F2N6O3Pureza:98.31%Cor e Forma:SolidPeso molecular:522.55ATI-2341
CAS:<p>ATI-2341, pepducin targeting the CXCR4, is an allosteric agonist activating the Gi to promote inhibition of cAMP production and induce calcium mobilization.</p>Fórmula:C104H178N26O25S2Cor e Forma:SolidPeso molecular:2256.82Peptide R TFA
<p>Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. It demonstrates excellent tumor stroma remodeling capabilities and is applicable in research on solid tumors, such as glioblastoma.</p>Fórmula:C39H57N13O8S2·xC2HF3O2Cor e Forma:SolidPeso molecular:900.08 (free base)Motixafortide
CAS:<p>Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).</p>Fórmula:C97H144FN33O19S2Pureza:98%Cor e Forma:SolidPeso molecular:2159.52CXCR2 antagonist 8
CAS:<p>CXCR2 antagonist 8 is a selective CXCR2 antagonist, which can be used for the treatment and prevention of insulin resistance.</p>Fórmula:C14H13N3O5Cor e Forma:SolidPeso molecular:303.27PS372424 hydrochloride
CAS:<p>PS372424 hydrochloride,CXCR3 agonist. Anti-inflammatory. Inhibits T-cell migration.</p>Fórmula:C33H45ClN6O4Pureza:95.03%Cor e Forma:SolidPeso molecular:625.2SRT3109
CAS:<p>SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.</p>Fórmula:C18H23F2N5O4S2Pureza:99.65% - 99.92%Cor e Forma:SolidPeso molecular:475.53MSX-122
CAS:<p>MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).</p>Fórmula:C16H16N6Pureza:98.31% - 98.94%Cor e Forma:SolidPeso molecular:292.34Plerixafor
CAS:<p>Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.</p>Fórmula:C28H54N8Pureza:99.17% - >99.99%Cor e Forma:SolidPeso molecular:502.78UNBS5162
CAS:<p>UNBS5162 (UNBS-5162) is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.</p>Fórmula:C17H18N4O3Pureza:98.37% - 99.97%Cor e Forma:SolidPeso molecular:326.35WZ811
CAS:<p>WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).</p>Fórmula:C18H18N4Pureza:99.42% - ≥95%Cor e Forma:SolidPeso molecular:290.36Baohuoside I
CAS:<p>Baohuoside I (Icariside-II) is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.</p>Fórmula:C27H30O10Pureza:97.64% - 98.14%Cor e Forma:SolidPeso molecular:514.52USL311
CAS:<p>USL311 blocks CXCR4/SDF-1 interaction, inhibits tumor cell growth and migration.</p>Fórmula:C24H34N6OPureza:98.46% - 99.56%Cor e Forma:SolidPeso molecular:422.57SB225002
CAS:<p>SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.</p>Fórmula:C13H10BrN3O4Pureza:98.16% - 99.85%Cor e Forma:SolidPeso molecular:352.14JMS-17-2
CAS:<p>JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).</p>Fórmula:C25H26ClN3OPureza:98.7% - 99.44%Cor e Forma:SolidPeso molecular:419.95Reparixin
CAS:<p>Reparixin inhibits CXCR1 (IC50=1 nM) strongly, CXCR2 weakly (IC50=100 nM), and it's a CXCL8 receptor blocker.</p>Fórmula:C14H21NO3SPureza:98% - 99.89%Cor e Forma:SolidPeso molecular:283.39Mavorixafor trihydrochloride
CAS:<p>Mavorixafor trihydrochloride blocks CXCR4 (IC50: 13 nM) and suppresses T-tropic HIV-1 replication (IC50: 1-9 nM). It's orally active.</p>Fórmula:C21H30Cl3N5Pureza:98.00%Cor e Forma:SolidPeso molecular:458.86Navarixin
CAS:<p>Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil</p>Fórmula:C21H23N3O5Pureza:98% - 99.51%Cor e Forma:SolidPeso molecular:397.42MSX-127
CAS:<p>MSX-127 elicites positive response in peptide CXCR4.</p>Fórmula:C16H24N2O4Pureza:98.43%Cor e Forma:SolidPeso molecular:308.37MSX-130
CAS:<p>MSX-130 is CXCR4 Antagonist.</p>Fórmula:C36H26N4Pureza:99.19%Cor e Forma:SolidPeso molecular:514.62JMS-17-2 hydrochloride
CAS:<p>JMS-17-2 hydrochloride: potent CX3CR1 blocker, IC50 of 0.32 nM, hinders breast cancer metastasis.</p>Fórmula:C25H27Cl2N3OCor e Forma:SolidPeso molecular:456.41CTCE 9908 acetate
<p>CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells.</p>Fórmula:C88H151N27O25Pureza:98.47%Cor e Forma:SolidPeso molecular:1987.31ATI-2341 acetate(1337878-62-2 free base)
<p>ATI-2341 acetate is an effective allosteric agonist of CXCR4, it activates Gα1 instead of Gα13.</p>Fórmula:C106H182N26O27S2Pureza:97.14%Cor e Forma:SolidPeso molecular:2316.87Elubrixin HCl
CAS:<p>Elubrixin is a interleukin 8 inhibitor and CXCR2 selective antagonist.</p>Fórmula:C17H18Cl3FN4O4SCor e Forma:SolidPeso molecular:499.77NUCC-390 dihydrochloride
CAS:<p>NUCC-390, a selective CXCR4 agonist, promotes nerve repair by inducing CXCR4 internalization, opposite to AMD3100.</p>Fórmula:C23H35Cl2N5OCor e Forma:SolidPeso molecular:468.46Decursin
CAS:<p>Decursin: potential antiepileptic, hepatoprotective, anti-cancer, anti-amnesic; affects NOX activation, PKCα/MAPK/NF-κB pathways, AChE.</p>Fórmula:C19H20O5Pureza:97.22% - 99.84%Cor e Forma:SolidPeso molecular:328.36FC131 TFA (606968-52-9 free base)
CAS:<p>FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv</p>Fórmula:C38H48F3N11O8Pureza:99.39% - 99.67%Cor e Forma:SolidPeso molecular:843.85AZD-5069
CAS:<p>AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).</p>Fórmula:C18H22F2N4O5S2Pureza:98.38% - 98.63%Cor e Forma:SolidPeso molecular:476.52ML339
CAS:<p>ML339 a selective inhibitor of CXCR6(IC50 = 140 nM) with no response when screened against CXCR5 and CXCR4.</p>Fórmula:C26H32ClN3O5Pureza:99.9%Cor e Forma:SolidPeso molecular:502AMD 3465 hexahydrobromide
CAS:<p>AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.</p>Fórmula:C24H44Br6N6Pureza:99.39%Cor e Forma:SolidPeso molecular:896.07SB-265610
CAS:<p>SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist.</p>Fórmula:C14H9BrN6OPureza:99.5%Cor e Forma:SolidPeso molecular:357.16Danirixin
CAS:<p>Danirixin (GSK1325756) is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).</p>Fórmula:C19H21ClFN3O4SPureza:99.78% - >99.99%Cor e Forma:SolidPeso molecular:441.9SX-682
CAS:<p>SX-682 is an orally available allosteric inhibitor of CXCR1 and CXCR2.Cost-effective and quality-assured.</p>Fórmula:C19H14BF4N3O4SPureza:98.19% - 99.57%Cor e Forma:SolidPeso molecular:467.2Nicotinamide N-oxide
CAS:<p>Nicotinamide N-oxide, a metabolite of nicotinamide and precursor to NAD+, is reduced by liver enzyme xanthine oxidase.</p>Fórmula:C6H6N2O2Pureza:99.66% - 99.9%Cor e Forma:SolidPeso molecular:138.12Plerixafor octahydrochloride
CAS:<p>Plerixafor octahydrochloride mobilizes HSCs by blocking SDF-1alpha/CXCR4 interaction, facilitating their release into circulation.</p>Fórmula:C28H62Cl8N8Pureza:98.01% - 99.79%Cor e Forma:SolidPeso molecular:794.46TAK-779
CAS:<p>TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).</p>Fórmula:C33H39ClN2O2Pureza:99.21%Cor e Forma:SolidPeso molecular:531.13AMD-070 hydrochloride
CAS:<p>AMD-070 hydrochloride is a CXCR4 antagonist, is useful for Anti HIV.</p>Fórmula:C21H28ClN5Pureza:98.38% - 98.57%Cor e Forma:SolidPeso molecular:385.93ML 145
CAS:<p>ML 145 is a selective antagonist of GPR35/CXCR8 (IC50/EC50 of 20.1 nM)</p>Fórmula:C24H22N2O5S2Pureza:97.74%Cor e Forma:SolidPeso molecular:482.57HF51116
CAS:<p>HF51116 blocks XCR4, hinders SDF-1α cell effects & HIV-1; potential for HIV, stem cells, cancer spread.</p>Fórmula:C29H46N8OCor e Forma:SolidPeso molecular:522.73CXCR3 Antagonist 6c
CAS:<p>CXCR3 antagonist 6c blocks CXCR3 and inhibits Ca2+ movement and T-cell migration (IC50: 0.06 µM & 100 nM) with selectivity over 14 other GPCRs.</p>Fórmula:C30H32Cl3N5O3Cor e Forma:SolidPeso molecular:616.97CXCR4 antagonist 9
CAS:<p>CXCR4 antagonist 9, with IC50s of 15 nM & 1.3 nM against CXCR4 & Ca²⁺ rise by CXCL12 respectively.</p>Fórmula:C21H27FN6Cor e Forma:SolidPeso molecular:382.48VUF10132
CAS:<p>VUF10132 is a full inverse CXCR3 N3.35A agonist.</p>Fórmula:C19H13BrCl4N2O2Pureza:98%Cor e Forma:SolidPeso molecular:523.03AMG 487 (S-enantiomer)
CAS:<p>AMG 487 S-enantiomer is the S enantiomer of AMG 487. AMG 487 is an CXCR3 antagonist.</p>Fórmula:C32H28F3N5O4Pureza:98%Cor e Forma:SolidPeso molecular:603.59HF50731
CAS:<p>HF50731 is a CXCR4 antagonist with high binding affinity (IC50: 19.8 nM) and inhibits calcium mobilization, cell migration, and HIV-1 (IC50: 1.5 nM).</p>Fórmula:C26H46N4Cor e Forma:SolidPeso molecular:414.67SRT3190
CAS:<p>SRT3190 is an antagonist of CXCR2.</p>Fórmula:C18H23F2N5O4S2Pureza:98%Cor e Forma:SolidPeso molecular:475.53CXCR4 modulator-2
CAS:<p>CXCR4 modulator-2 (Z7R) has high potency (IC50: 1.25 nM), stable in mouse serum (t1/2=77.1 min), and anti-inflammatory in mice.</p>Fórmula:C21H32N8O2Cor e Forma:SolidPeso molecular:428.53ICT5040
CAS:<p>ICT5040 is a CXCR4 antagonist.</p>Fórmula:C10H8F3N3OSCor e Forma:SolidPeso molecular:275.25SB-332235
CAS:<p>SB-332235 is an effective specific CXCR2 antagonist. And it is effectively inhibited CS-induced neutrophilia in a dose-dependent manner.</p>Fórmula:C13H10Cl3N3O4SCor e Forma:SolidPeso molecular:410.66VUF11211
CAS:<p>VUF11211 is an effective antagonist of CXCR3 that acts by extending from the minor pocket into the major pocket of the transmembrane domains.</p>Fórmula:C26H35Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:504.49TN-14003
CAS:<p>TN-14003 is a synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model.</p>Fórmula:C90H141N33O18S2Cor e Forma:SolidPeso molecular:2037.42CXCR4 antagonist 8
CAS:<p>CXCR4 antagonist 8 (Compound 3) blocks CXCR4, IC50 of 57 nM; stops CXCL12-induced Ca2+ increase, IC50 of 0.24 nM; hinders cell migration.</p>Fórmula:C21H26N6Cor e Forma:SolidPeso molecular:362.47CXCR4 antagonist 5
CAS:<p>CXCR4 antagonist with IC50 of 8.8 nM, inhibits CXCL12-induced calcium increase and chemotaxis, with good safety and minimal CYP, hERG impact.</p>Fórmula:C21H30N6Cor e Forma:SolidPeso molecular:366.5SX-517
CAS:<p>SX-517 is a non-competitive dual antagonist of CXCR1/2, demonstrating anti-inflammatory effects, inhibits CXCL-1-induced Ca²⁺ flux.</p>Fórmula:C19H16BFN2O3SCor e Forma:SolidPeso molecular:382.22KRH-1636
CAS:<p>KRH-1636: potent, selective CXCR4 antagonist; orally active; inhibits X4 HIV-1 by blocking viral entry and membrane fusion.</p>Fórmula:C32H37N7O2Cor e Forma:SolidPeso molecular:551.68IT1t
CAS:<p>IT1t inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM. is a potent CXCR4 antagonist.</p>Fórmula:C21H34N4S2Pureza:98%Cor e Forma:SolidPeso molecular:406.65Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Fórmula:C27H52BrN8O3PPureza:98%Cor e Forma:SolidPeso molecular:647.644VUF5834
CAS:<p>VUF5834 is a full inverse agonist of CXCR3 N3.35A.</p>Fórmula:C31H41N5O2Pureza:98%Cor e Forma:SolidPeso molecular:515.69rac-NBI-74330
CAS:<p>rac-NBI-74330 is an effective and selective CXCR3 antagonist.</p>Fórmula:C32H27F4N5O3Pureza:99.6%Cor e Forma:SolidPeso molecular:605.58PS372424
CAS:<p>PS372424 is a specific agonist of human CXCR3, with anti-inflammatory activity.</p>Fórmula:C33H44N6O4Pureza:98%Cor e Forma:SolidPeso molecular:588.74AZ10397767
CAS:<p>AZ10397767: Potent CXCR2 blocker (IC50=1nM); lowers neutrophil infiltration in tumors in vitro/in vivo.</p>Fórmula:C15H14ClFN4O2S2Cor e Forma:SolidPeso molecular:400.88AMD 3465
CAS:<p>AMD 3465 (GENZ-644494) blocks CXCR4, hinders X4 HIV replication (IC50: 1-10 nM), ineffective against R5 viruses, IC50: 0.75 nM (12G5 mAb), 18 nM (CXCL12AF647).</p>Fórmula:C24H38N6Pureza:98%Cor e Forma:SolidPeso molecular:410.60SCH 546738
CAS:<p>SCH 546738 is an orally available, selective and potent CXCR3 antagonist that attenuates the development of autoimmune diseases and delays graft rejection.</p>Fórmula:C23H31Cl2N7OPureza:98.67%Cor e Forma:SolidPeso molecular:492.45GPR35 agonist 1
CAS:<p>GPR35 agonist 1 is a highly effective and specific GPR35/CXCR8 agonist (EC50: 5.8 nM).</p>Fórmula:C10H4BrN5O5Pureza:98%Cor e Forma:SolidPeso molecular:354.07SB02024
CAS:<p>SB02024 inhibits VPS34, boosts cGAS-STING, hinders autophagy, and shrinks breast cancer xenografts; enhances Sunitinib/Erlotinib efficacy.</p>Fórmula:C16H22F3N3O2Cor e Forma:SolidPeso molecular:345.36ACT-660602
CAS:<p>ACT-660602: Oral CXCR3 blocker, T-cell migration inhibitor, effective in acute lung injury models, potential for autoimmune research. IC50: 204 nM.</p>Fórmula:C20H20F6N8OSCor e Forma:SolidPeso molecular:534.48IT1t dihydrochloride
CAS:<p>IT1t dihydrochloride inhibits CXCL12/CXCR4 interaction with IC50 of 2.1 nM. IT1t dihydrochloride is an antagonist of CXCR4.</p>Fórmula:C21H36Cl2N4S2Pureza:99.91%Cor e Forma:SolidPeso molecular:479.57Mavorixafor
CAS:<p>Mavorixafor (AMD-070) is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding.</p>Fórmula:C21H27N5Pureza:98.56%Cor e Forma:SolidPeso molecular:349.47NUCC-390
CAS:<p>NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100.</p>Fórmula:C23H33N5OPureza:97.08%Cor e Forma:SolidPeso molecular:395.54AZD8797
CAS:<p>AZD8797 (KAND567) is a CX3CR1 antagonist with potential protective effects against neuronal damage and prevents nociceptive hypersensitivity in rats.</p>Fórmula:C19H25N5OS2Pureza:98.73% - 99.68%Cor e Forma:SolidPeso molecular:403.56Elubrixin
CAS:<p>Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM).</p>Fórmula:C17H17Cl2FN4O4SPureza:98.65% - 99.78%Cor e Forma:SolidPeso molecular:463.31AZD8309
CAS:<p>AZD8309 is an oral CXCR2 antagonist, curbing neutrophil movement, lowering MPO in lungs/pancreas, and trypsin/elastase activity.</p>Fórmula:C15H14F2N4O2S2Pureza:98.35% - 99.67%Cor e Forma:SolidPeso molecular:384.42TIQ-15
CAS:<p>TIQ-15 is an effective and selective CXCR4 antagonist. It has good drug-like properties.</p>Fórmula:C23H32N4Pureza:98%Cor e Forma:SolidPeso molecular:364.53CXCR4 antagonist 6
CAS:<p>CXCR4 antagonist 6 blocks CXCR4 (IC50: 79 nM), hinders calcium flux (IC50: 0.25 nM), reduces cell migration, and is effective in cancer metastasis mice.</p>Fórmula:C21H30N6Cor e Forma:SolidPeso molecular:366.5Ladarixin Sodium
CAS:<p>Ladarixin Sodium, an Chemokine CXCR antagonist, is used potentially for the treatment of type I diabetes.</p>Fórmula:C11H12F3NNaO6S2Cor e Forma:SolidPeso molecular:398.32(±)-AMG 487
<p>AMG 487 is an effective and selective antagonist of chemokine receptor 3.</p>Fórmula:C32H28F3N5O4Pureza:98%Cor e Forma:SolidPeso molecular:603.59Pentixafor
CAS:<p>Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission</p>Fórmula:C60H80N14O14Pureza:98%Cor e Forma:SolidPeso molecular:1221.36CXCR4 antagonist 7
CAS:<p>Compound PARA-B, a CXCR4 antagonist with IC50 = 9.3 nM, targets HIV, cancer, inflammatory diseases, and WHIM syndrome.</p>Fórmula:C15H17N5O3Cor e Forma:SolidPeso molecular:315.33CXCR2 antagonist 2
CAS:<p>CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunotherapy with an IC 50 value of 95 nM.</p>Fórmula:C17H17FN2O4SCor e Forma:SolidPeso molecular:364.39NUCC-390 dihydrochloride (1060524-97-1 free base)
<p>NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.</p>Fórmula:C23H35Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:468.46CXCR2-IN-2
CAS:<p>CXCR2-IN-2: A selective, brain-penetrant, oral CXCR2 inhibitor (IC50: 5.2 nM/1 nM). ~730x selectivity vs CXCR1, >1900x vs other chemokine receptors.</p>Fórmula:C18H23ClN2O5SCor e Forma:SolidPeso molecular:414.9E6130
CAS:<p>E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.</p>Fórmula:C28H37ClF3N3O3Cor e Forma:SolidPeso molecular:556.06CXCR2 antagonist 3
CAS:<p>Compound 11h, a CXCR2 antagonist, inhibits neutrophil/MDSCs and boosts CD3+ T cells in Pan02 tumors.</p>Fórmula:C17H15FN2O4SCor e Forma:SolidPeso molecular:362.38(R,R)-CXCR2-IN-2
CAS:<p>'(R,R)-CXCR2-IN-2 is a brain-penetrating diastereoisomer and CXCR2 antagonist with pIC50 of 9 (Tango) and 6.8 (HWB Gro-α/CD11b).'</p>Fórmula:C18H23ClN2O5SCor e Forma:SolidPeso molecular:414.9CXCR2-IN-1
CAS:<p>CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.</p>Fórmula:C19H20Cl2FN3O4SPureza:99.89%Cor e Forma:SolidPeso molecular:476.35EMU-116
CAS:<p>EMU-116 is an orally active antagonist of CXCR4, utilized in cancer research.</p>Fórmula:C25H35N5Cor e Forma:SolidPeso molecular:405.58CXCR4 modulator-1
CAS:<p>CXCR4 modulator-1 (ZINC72372983) is potent (EC50=100nM) with uses in anti-inflammatory, anticancer, and anti-HIV research.</p>Fórmula:C23H27N5O2Cor e Forma:SolidPeso molecular:405.49ACT-777991
CAS:<p>ACT-777991: oral CXCR3 blocker, stable in microsomes/hepatocytes, inhibits T-cell migration to CXCL11.</p>Fórmula:C20H20F6N8O2SCor e Forma:SolidPeso molecular:550.48(R)-SCH 546738
CAS:<p>(R)-SCH 546738, the R-isomer of SCH 546738, is a non-competitive, orally active antagonist targeting the CXCR3 receptor, exhibiting a K_i of 0.4 nM for the human CXCR3 receptor.</p>Fórmula:C23H31Cl2N7OCor e Forma:SolidPeso molecular:492.45CXCR4 antagonist 10
CAS:<p>CXCR4 antagonist10 (compound 21) is an effective CXCR4 inhibitor with an IC50 value of 7.8 nM. It plays a significant role in cancer research.</p>Fórmula:C18H18N4O4Cor e Forma:SolidPeso molecular:354.36CXCR4 antagonist 3
<p>CXCR4 antagonist 3, aka compound 12a, has 11 nM IC50, shares TIQ15 traits, and is promising in HIV research.</p>Fórmula:C22H31N5Cor e Forma:SolidPeso molecular:365.52CXCR7 modulator 2
CAS:<p>CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM.</p>Fórmula:C29H42N6O3Cor e Forma:SolidPeso molecular:522.68CXCR2 antagonist 4
<p>CXCR2 antagonist 4 inhibits CXCR2 (IC50: 0.13 μM) and CXCL8-induced calcium rise (IC50: 27 μM), promising for cancer research.</p>Fórmula:C15H14F2N4OS2Cor e Forma:SolidPeso molecular:368.42CXCR2 antagonist 6
<p>CXCR2 antagonist 6: strong CXCR2 affinity (IC50=0.044 μM), hinders calcium mobilization (IC50=0.66 μM).</p>Fórmula:C17H16F2N4OSCor e Forma:SolidPeso molecular:362.4Paeoniflorin-6′-O-benzene sulfonate
CAS:<p>Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.</p>Fórmula:C29H32O13SCor e Forma:SolidPeso molecular:620.622CXCR7 antagonist-1 hydrochloride
CAS:<p>CXCR7 antagonist-1 hydrochloride blocks SDF-1 and I-TAC from CXCR7; may prevent cancer and inflammation.</p>Fórmula:C21H20ClFN6OCor e Forma:SolidPeso molecular:426.87CXCR2 antagonist 5
<p>CXCR2 antagonist 5 (compound 25) binds strongly (IC50=0.013μM) and mobilizes calcium (IC50=0.1μM).</p>Fórmula:C15H14F2N4O2SCor e Forma:SolidPeso molecular:352.36SCH 563705
CAS:<p>SCH 563705 is a CXCR2 and CXCR1 antagonist used in the study of acute respiratory syndrome, chronic obstructive pulmonary disease, and inflammation.</p>Fórmula:C23H27N3O5Pureza:98.03%Cor e Forma:SolidPeso molecular:425.48SLW131
CAS:<p>SLW131 (Compound 10) is a CCR7 antagonist with strong affinity, showing a Ki of 9.85 nM. It inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM and β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also suppresses CCL19-induced morphological changes in primary BMDC cells and CCR7-mediated migration of mouse CD4+ T cells.</p>Fórmula:C21H27N5O5SCor e Forma:SolidPeso molecular:461.535CCX662
CAS:<p>CCX662 is a CXCR7 antagonist. It inhibits the binding of 125I-CXCL12 to CXCR7 with an IC50 of 9 nM. This compound is suitable for use in cancer research.</p>Fórmula:C28H37N5O4SCor e Forma:SolidPeso molecular:539.69CXCR2 antagonist 7
<p>CXCR2 antagonist 7 is a powerful blocker with IC50s: 0.044 μM for binding, 0.66 μM for calcium mobilization.</p>Fórmula:C14H14F2N6OSCor e Forma:SolidPeso molecular:352.36ACT-672125
CAS:<p>ACT-672125: Potent CXCR3 blocker, may treat autoimmunity, safe with dose-dependent efficacy in lung inflammation.</p>Fórmula:C25H25F3N10O2SCor e Forma:SolidPeso molecular:586.59VUF11207 trifluoroacetate salt
CAS:<p>VUF11207 trifluoroacetate salt is a useful organic compound for research related to life sciences. The catalog number is T66657 and the CAS number is 1378524-41-4.</p>Fórmula:C29H36F4N2O6Cor e Forma:SolidPeso molecular:584.609CXCR4-IN-1
CAS:<p>CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic</p>Fórmula:C23H32N6Pureza:98%Cor e Forma:SolidPeso molecular:392.54Ref: TM-T79059
Produto descontinuado
